The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Continuation of EGFR/ALK inhibition after local therapy of oligoprogressive disease in EGFR mutant (Mt) and ALK+ non-small cell lung cancer (NSCLC).
Andrew James Weickhardt
Honoraria - Pfizer
Benjamin Scheier
No relevant relationships to disclose
Joseph Malachy Burke
No relevant relationships to disclose
Gregory Gan
No relevant relationships to disclose
Robert Charles Doebele
Honoraria - Abbott Laboratories; Pfizer
Research Funding - ImClone Systems; Lilly; Pfizer
Paul A. Bunn
Employment or Leadership Position - IASLC
Consultant or Advisory Role - Agennix; Amgen; AstraZeneca; Bayer; Biodesix; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Daiichi Sankyo; GlaxoSmithKline; GlobeImmune; Lilly; Merck; Merrimack; Novartis; OSI Pharmaceuticals; Pfizer; Roche/Genentech; Sanofi
Honoraria - Agennix; Amgen; AstraZeneca; Bayer; Biodesix; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Daiichi Sankyo; GlaxoSmithKline; GlobeImmune; Lilly; Merck; Merrimack; Novartis; OSI Pharmaceuticals; Pfizer; Roche/Genentech; Sanofi
Laurie E. Gaspar
No relevant relationships to disclose
Brian D. Kavanagh
No relevant relationships to disclose
D. Ross Camidge
Consultant or Advisory Role - Astellas Pharma; OSI Pharmaceuticals; Pfizer
Honoraria - Pfizer
Research Funding - Pfizer